Vor Biopharma Inc.: directors' dealings · United States · SEC (Form 4)

About Vor Biopharma Inc.

Vor Biopharma Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq Global Select Market under the ticker VOR. The company is headquartered in Boston, Massachusetts, United States. It was founded in December 2015 and began operations in February 2016. Vor is currently a clinical-stage biotech with no approved commercial products, which places it squarely in the high-risk, high-upside segment of the life sciences market. For investors, the company remains highly dependent on clinical execution, regulatory progress, and access to capital. Vor Biopharma originally built its platform around blood-cancer programs and cell-engineering approaches, but its strategy has since shifted materially toward autoimmune disease. In June 2025, the company signed a license agreement with RemeGen that gives Vor exclusive rights, including sublicensing rights, to develop and commercialize telitacicept in all territories outside Greater China. RemeGen retains rights in mainland China, Hong Kong, Macau, and Taiwan. This transaction was transformative for Vor’s business model, because it effectively converted the company from a pre-commercial oncology-focused developer into an autoimmune franchise centered on one lead asset. Today, Vor’s core program is telitacicept, a fusion protein designed to inhibit both BAFF and APRIL, two key signaling pathways involved in B-cell survival and autoimmune activity. The company’s lead development priorities are generalized myasthenia gravis (gMG) and Sjögren’s disease (SjD). The most recent annual report states that telitacicept is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and gMG, which provides external clinical validation of the mechanism. However, that does not reduce the regulatory risk in the United States or Europe, where the asset still needs to complete late-stage development and secure approvals. From a competitive standpoint, Vor competes in a crowded biotech landscape where the main differentiator is often the quality of clinical data rather than commercial scale. The company’s potential edge lies in the dual BAFF/APRIL mechanism and in the fact that it can leverage prior Chinese trial data from RemeGen. Vor says it initiated a global Phase 3 study in SjD with first patient dosing in March 2026, recruiting patients across the United States, Europe, South America, and Asia. It is also advancing a global Phase 3 program in gMG. Recent catalysts have been meaningful. In 2025, Vor finalized the RemeGen licensing deal and presented Phase 3 data at medical congresses. In March 2026, it dosed the first patient in its global SjD Phase 3 study. The company also announced a private placement in late March 2026, expected to generate about $75 million in gross proceeds. More recently, SEC Form 4 filings showed sales by RA Capital-related entities, which investors often monitor as a sentiment signal, although such transactions do not necessarily imply a change in the long-term thesis. Overall, Vor Biopharma remains a development-stage biotech on Nasdaq in the United States, with valuation primarily driven by the next clinical readouts and the company’s ability to finance execution through regulatory milestones.